Disease relevance of PENTAMETHYLMELAMINE

• Biochemical studies on the ability of pentamethylmelamine to interact in vivo with DNA and proteins in a sensitive murine ovarian reticular cell sarcoma [1].

High impact information on PENTAMETHYLMELAMINE

• The disposition of both hexamethylmelamine (HMM) after intraarterial, i.v., portal vein, and intraduodenal administration and of pentamethylmelamine following its i.v. administration was studied in male Wistar rats [2].
• Uptake and metabolism of hexamethylmelamine and pentamethylmelamine by L5178Y lymphoblasts in vitro [3].
• HMM, PMM, and 2,2,4,6 TetrMM concentrations determined in RC tissues were much higher than the plasma values, as indicated by the pharmacokinetic parameters (Cmax and AUC) [4].
• N2,N4,N6-Trihydroxymethyl-N2,N4,N6-trimethylmelamine (Trimelamol) is a water-soluble synthetic s-triazine which, unlike hexamethylmelamine (HMM) and pentamethylmelamine (PMM), does not require metabolic activation [5].
• Tissue distribution of pentamethylmelamine (PMM), 2,2,4,6-tetramethylmelamine (TMM), and 2,4,6-trimethylmelamine (TriMM) was determined at the three times considered [6].

Biological context of PENTAMETHYLMELAMINE

• The comparative pharmacokinetics of pentamethylmelamine in man, rat, and mouse [7].
• The rational development of analogs based on structure-activity relationships and on overcoming pharmacologic or toxicologic problems of parent compounds requires much future emphasis; two such examples (pentamethylmelamine and AZQ) are cited here [8].

Anatomical context of PENTAMETHYLMELAMINE

• Human central nervous system pharmacology of pentamethylmelamine and its metabolites [9].
• The intestinal oxidative metabolism of hexamethylmelamine (HMM) and pentamethylmelamine (PMM) has been studied in microsomes, isolated mucosal cells and intestinal perfused segments [10].

Gene context of PENTAMETHYLMELAMINE

• The pharmacokinetics of pentamethylmelamine (PMM) have been investigated in mouse (Balb C-, CBA/LAC, nude), rat (Wistar), and man [7].

Analytical, diagnostic and therapeutic context of PENTAMETHYLMELAMINE

• Phase I and pharmacological studies of pentamethylmelamine administered by 24-hour intravenous infusion [11].
• HMM (5 and 10 mg/kg) and pentamethylmelamine (5 mg/kg) were infused via implanted cannulas into conscious animals (n greater than or equal to 4) [2].
• Specific determination of pentamethylmelamine and its demethylated metabolites in human plasma by high pressure liquid chromatography [12].
• Determination of pentamethylmelamine and hexamethylmelamine in plasma and urine by nitrogen-phosphorus gas-liquid chromatography [13].
• Two of the derivatives, pentamethylmelamine and N2, N4, N6-trimethyl-N2, N4, N6-trimethylolmelamine, which have shown activity against the xenograft are potential candidates for clinical trials using the intravenous route of administration [14].

References